Study of GS-0151 in Participants With Rheumatoid Arthritis

2024-516520-34-00 Protocol GS-US-667-6882 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 17 Nov 2025 · Status Ongoing, recruiting · 3 EU/EEA countries · 15 sites · Protocol GS-US-667-6882

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 114
Countries 3
Sites 15

Rheumatoid Arthritis

Key facts

Sponsor
Gilead Sciences Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
17 Nov 2025 → ongoing
Decision date (initial)
2025-08-20
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Rheumatoid Arthritis

VersionLevelCodeTermSystem organ class
23.1 PT 10039073 Rheumatoid arthritis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Gilead Sciences Inc.

Sponsor organisation
Gilead Sciences Inc.
Address
333 Lakeside Drive
City
Foster City
Postcode
94404-1147
Country
United States

Scientific contact point

Organisation
Gilead Sciences Inc.
Contact name
EU CT Support

Public contact point

Organisation
Gilead Sciences Inc.
Contact name
EU CT Support

Locations

3 EU/EEA countries · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 13 4
Poland Ongoing, recruiting 12 6
Spain Ongoing, recruiting 14 5
Rest of world
United States, Moldova, Republic of, Georgia
75

Investigational sites

Germany

4 sites · Ongoing, recruiting
University Hospital Cologne AöR
Med. Klinik 1 für Innere Medizin, Kerpener Strasse 62, Lindenthal, Cologne
Krankenhaus Porz Am Rhein gGmbH
Klinik für Rheumatologie, Urbacher Weg 19, Porz, Cologne
LMU Klinikum Muenchen AöR
Medizinische Klinik & Poliklinik IV, Pettenkoferstrasse 8a, Ludwigsvorstadt-Isarvorstadt, Munich
MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH
Hamburger Rheuma Forschungszentrum II, Moenckebergstrasse 27, Hamburg-Altstadt, Hamburg

Poland

6 sites · Ongoing, recruiting
Futuremeds Sp. z o.o.
FutureMeds Warszawa Targówek - site, Ul. Sw. Wincentego 93 Lok. 5/6/7, 03-291, Warsaw
Futuremeds Sp. z o.o.
FutureMeds Gdynia - site, Ul. Wladyslawa IV 59, 81-384, Gdynia
Futuremeds Sp. z o.o.
FutureMeds Łódź - site, Ul. Gruszowa 2, 91-363, Lodz
Futuremeds Sp. z o.o.
FutureMeds Wroclaw - site, Ul. Legnicka 16, 53-673, Wroclaw
Medicover Integrated Clinical Services Sp. z o.o.
MICS Centrum Medyczne Toruń, Ul. Stefana Batorego 18-22, 87-100, Torun
Clinicmed Daniluk Nowak Sp. k.
n/a, Ul. Stoleczna 7/200, 15-879, Bialystok

Spain

5 sites · Ongoing, recruiting
Parc Tauli Hospital Universitari
Rheumatology, Parc Del Tauli 1, 08208, Sabadell
Hospital Universitario Ramon Y Cajal
Rheumatology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Quironsalud Infanta Luisa
Rheumatology, Calle De San Jacinto 87, 41010, Sevilla
Hospital Del Mar
Rheumatology, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
Area Sanitaria Da Coruna E Cee
Rheumatology, Lugar Jubias De Arriba Num 84, 15006, A Coruna

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-11-17 2026-01-07
Poland 2025-11-21 2025-12-11
Spain 2025-11-18 2026-03-04

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-28 Germany Acceptable
2025-08-18
2025-08-20
2 SUBSTANTIAL MODIFICATION SM-1 2025-09-23 Acceptable 2025-10-28
3 SUBSTANTIAL MODIFICATION SM-2 2025-09-25 Germany Acceptable 2025-10-13
4 SUBSTANTIAL MODIFICATION SM-3 2026-03-27 Germany Acceptable
2026-05-26
2026-05-29